City of Hope provides $2.3 mln in Series A funding in Lumināt

City of Hope, a research and treatment center for cancer, diabetes and other diseases, has provided $2.3 million in Series A funding to Lumināt, which develops advance care planning. City of Hope also has granted Lumināt a license to develop and market the company’s touch-screen tool to assess patient needs. Lumināt raised initial seed funding of $750,000. The Series A funding is the first of its kind from City of Hope.

Press Release

Lumināt, LLC, an industry-­leading advance care planning developer, announced today that it has secured $2.3 million in Series A funding from City of Hope.

In addition to the funding, City of Hope has granted Lumināt a perpetual license to further develop and market SupportScreen, its automated touch-­screen tool to assess patient needs.

“We are pleased to support Lumināt in its next phase of growth,” said City of Hope Chief Financial Officer Ric Magnuson. “Like City of Hope, Lumināt is committed to enhancing patient care through innovative technology solutions, and we believe this partnership will deliver essential products to patients, family members and their medical providers.”

The financing follows Lumināt’s initial seed investment of $750,000. Lumināt’s leadership team, consisting of experienced healthcare executives with demonstrated success in bringing new products to market, will leverage this round of funding to enhance and expand its product offerings and reposition itself in the industry.

“City of Hope is an ideal partner as we enter this next stage of development,” said Tom Valdivia, M.D., M.S., chief executive officer of Lumināt. “The financial support and industry knowledge that City of Hope brings will help us develop a comprehensive line of supportive care services and patient generated health information technologies faster, more broadly and with greater expertise.”

The Series A funding for Lumināt is the first of its kind from City of Hope.

“City of Hope is confident in the success of the investment, the co-­development and the licensing partnership, as well as the qualified team at Lumināt,” said George Megaw, director of technology licensing at City of Hope. “Together, we will accelerate City of Hope’s efforts to propagate the SupportScreen technology to more patients.”

About Lumināt
Lumināt (pronounced loo-­mi-­nate) is a software company that helps individuals consider, articulate and preserve their end-­of-life wishes. Lumināt’s essential, turnkey tool facilitates a necessary, though often very difficult conversation through an easy-­to-­use, customized and interactive platform. Lumināt’s cloud-­based technology gives users and family members peace of mind knowing an individual’s complete wishes, from medical care to spiritual and financial requests, are documented and can be easily retrieved during critical moments. Visit for more information.

About City of Hope
City of Hope is a leading research and treatment center for cancer, diabetes and other life-­threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope’s main hospital is located in Duarte, Calif., just northeast of Los Angeles, with community clinics in southern California. It is ranked as one of “America’s Best Hospitals” in cancer by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.